- •Two HBV-infected patients with incomplete viral suppression despite dual entecavir (ETV) and tenofovir (TDF) therapy carried the rtS78T/sC69∗ HBV mutation.
- •The rtS78T mutation causes enhanced viral replication and reduced susceptibility to ETV and TDF in vitro.
- •The sC69∗ mutation causes truncation of HBs protein without defective HBV secretion or intracellular HBsAg retention.
- •This mutation selected during ETV + TDF therapy may predispose to treatment failure and HBV-related carcinogenesis.
Background & Aims
Purchase one-time access:Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
One-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Author names in bold designate shared co-first authorship
- The global burden of viral hepatitis from 1990 to 2013: findings from the Global Burden of Disease Study 2013.Lancet. 2016; 388: 1081-1088
- EASL clinical practice guidelines: Management of chronic hepatitis B virus infection.J Hepatol. 2012; 57: 167-185
- Optimal management of chronic hepatitis B patients with treatment failure and antiviral drug resistance.Liver Int. 2013; 33: 116-124
- AASLD guidelines for treatment of chronic hepatitis B.Hepatology. 2016; 63: 261-283
- Entecavir treatment for up to 5 years in patients with hepatitis B e antigen-positive chronic hepatitis B.Hepatology. 2010; 51: 422-430
- Impact of hepatitis B e antigen-suppressing mutations on the replication efficiency of entecavir-resistant hepatitis B virus strains.J Viral Hepat. 2011; 18: 804-814
- Seven-year efficacy and safety of treatment with tenofovir disoproxil fumarate for chronic hepatitis B virus infection.Dig Dis Sci. 2015; 60: 1457-1464
- Selection of hepatitis B virus polymerase mutations in HIV-coinfected patients treated with tenofovir.Antivir Ther. 2005; 10: 727-734
- The rtA194T polymerase mutation impacts viral replication and susceptibility to tenofovir in hepatitis B e antigen-positive and hepatitis B e antigen-negative hepatitis B virus strains.Hepatology. 2009; 49: 1158-1165
- Overview of hepatitis B viral replication and genetic variability.J Hepatol. 2016; 64: S4-S16
- Ultra-deep pyrosequencing of hepatitis B virus quasispecies from nucleoside and nucleotide reverse-transcriptase inhibitor (NRTI)-treated patients and NRTI-naive patients.J Infect Dis. 2009; 199: 1275-1285
- Prevalence, viral replication efficiency and antiviral drug susceptibility of rtQ215 polymerase mutations within the hepatitis B virus genome.J Hepatol. 2009; 51: 647-654
- Hepatitis delta virus facilitates the selection of hepatitis B virus mutants in vivo and functionally impacts on their replicative capacity in vitro.Clin Microbiol Infect. 2016; 22: e91-e96
- Basal core promoter and precore mutations in the hepatitis B virus genome enhance replication efficacy of Lamivudine-resistant mutants.J Virol. 2004; 78: 8524-8535
- Exosomes mediate hepatitis B virus (HBV) transmission and NK-cell dysfunction.Cell Mol Immunol. 2016;
- Differential impact of immune escape mutations G145R and P120T on the replication of lamivudine-resistant hepatitis B virus e antigen-positive and -negative strains.J Virol. 2010; 84: 1026-1033
- Anti-HBV treatment induces novel reverse transcriptase mutations with reflective effect on HBV S antigen.J Infect. 2013; 67: 303-312
- Naturally occurring mutations in large surface genes related to occult infection of hepatitis B virus genotype C.PLoS One. 2013; 8e54486
- Hepatitis B virus X protein stimulates gene expression selectively from extrachromosomal DNA templates.Hepatology. 2012; 56: 2116-2124
- Characterization of novel hepatitis B virus PreS/S-gene mutations in a patient with occult hepatitis B virus infection.PLoS One. 2016; 11e0155654
- Effects of amino acid substitutions in hepatitis B virus surface protein on virion secretion, antigenicity, HBsAg and viral DNA.J Hepatol. 2017; 66: 288-296
- Single-molecule sequencing reveals complex genome variation of hepatitis B virus during 15 years of chronic infection following liver transplantation.J Virol. 2016; 90: 7171-7183
- The antiviral drug selected hepatitis B virus rtA181T/sW172∗ mutant has a dominant negative secretion defect and alters the typical profile of viral rebound.Hepatology. 2008; 48: 88-98
- Hepatocarcinogenesis associated with hepatitis B, delta and C viruses.Curr Opin Virol. 2016; 20: 1-10
- Identification of transforming hepatitis B virus S gene nonsense mutations derived from freely replicative viruses in hepatocellular carcinoma.PLoS One. 2014; 9e89753
- Clinical emergence of entecavir-resistant hepatitis B virus requires additional substitutions in virus already resistant to Lamivudine.Antimicrob Agents Chemother. 2004; 48: 3498-3507
- Analysis of potential antiviral resistance mutation profiles within the HBV reverse transcriptase in untreated chronic hepatitis B patients using an ultra-deep pyrosequencing method.Diagn Microbiol Infect Dis. 2014; 79: 25-30
- Entecavir resistance is rare in nucleoside naive patients with hepatitis B.Hepatology. 2006; 44: 1656-1665
- Two-year assessment of entecavir resistance in Lamivudine-refractory hepatitis B virus patients reveals different clinical outcomes depending on the resistance substitutions present.Antimicrob Agents Chemother. 2007; 51: 902-911
- Differential binding of tenofovir and adefovir to reverse transcriptase of hepatitis B virus.PLoS One. 2014; 9e106324
- The L80I substitution in the reverse transcriptase domain of the hepatitis B virus polymerase is associated with lamivudine resistance and enhanced viral replication in vitro.Antimicrob Agents Chemother. 2007; 51: 2285-2292
- Core promoter: a critical region where the hepatitis B virus makes decisions.World J Gastroenterol. 2014; 20: 425-435
- Viral and cellular determinants involved in hepadnaviral entry.World J Gastroenterol. 2007; 13: 22-38
- Molecular biology of hepatitis B virus infection.Virology. 2015; 479–480: 672-686